Forrest Classification for Bleeding Peptic Ulcers
The Forrest classification stratifies bleeding peptic ulcers into high-risk lesions requiring endoscopic hemostasis (Forrest Ia, Ib, IIa) versus low-risk lesions managed with PPI therapy alone (Forrest IIc, III), with Forrest IIb (adherent clot) representing a controversial intermediate category.
Classification System
The Forrest classification divides bleeding ulcers into six categories based on endoscopic appearance 1, 2:
High-Risk Stigmata (Require Endoscopic Hemostasis)
- Forrest Ia: Spurting/arterial bleeding - active pulsatile hemorrhage
- Forrest Ib: Oozing bleeding - active non-pulsatile hemorrhage
- Forrest IIa: Non-bleeding visible vessel - raised pigmented protuberance in ulcer base
Intermediate Risk
- Forrest IIb: Adherent clot - overlying clot adherent to ulcer base
Low-Risk Stigmata (No Endoscopic Hemostasis Needed)
- Forrest IIc: Flat pigmented spot - non-protuberant pigmented dot
- Forrest III: Clean ulcer base - no stigmata of hemorrhage
Important caveat: Forrest Ib (oozing) actually carries lower rebleeding risk than Forrest IIa (visible vessel) or IIb (adherent clot), despite being classified as "active" bleeding 2.
Management Algorithm by Forrest Grade
Forrest Ia and Ib (Active Bleeding)
Endoscopic therapy is mandatory 1:
Dual therapy required: Epinephrine injection (1:10,000) PLUS a second modality 1
- Epinephrine alone provides suboptimal efficacy and should never be used as monotherapy
- Second modality options: thermocoagulation (heater probe, bipolar, APC), clips, or sclerosant injection
- No single thermal method is superior to another 1
Pharmacologic management:
Hospitalization: Minimum 72 hours after endoscopic hemostasis 1
Forrest IIa (Non-Bleeding Visible Vessel)
Endoscopic hemostasis is indicated - these lesions carry high rebleeding risk 1:
- Same dual therapy approach as Forrest Ia/Ib
- Same high-dose PPI regimen
- Same hospitalization duration
Forrest IIb (Adherent Clot)
This grade is controversial 1, 2:
- Attempt targeted irrigation to dislodge the clot 1
- If clot dislodges: Treat any underlying Forrest Ia, Ib, or IIa lesion with endoscopic hemostasis
- If clot remains adherent: Two acceptable approaches:
The WSES guidelines advocate a cautious, non-aggressive approach to clot dislodgment rather than mechanical removal 2. Individual endoscopist judgment is appropriate here, as evidence remains insufficient to mandate one approach.
PPI therapy: High-dose IV infusion for 72 hours regardless of whether endoscopic therapy is performed 1
Forrest IIc and III (Low-Risk Lesions)
No endoscopic hemostasis indicated - rebleeding risk is minimal 1:
- Standard oral PPI once daily 1
- Early discharge is appropriate - patients can be fed within 24 hours and discharged home 1
- No hospitalization required for observation in most cases
Exception: Patients with Forrest IIc lesions AND Rockall score ≥6 have significantly higher rebleeding risk (18.6% vs 2.9%) and warrant closer monitoring 3.
Additional Management Principles
Timing of Endoscopy
- Perform early endoscopy within 24 hours of presentation 1
- Very early endoscopy (<12 hours) for hemodynamically unstable patients despite resuscitation 4
Pre-Endoscopy Management
- Erythromycin 250 mg IV given 30-120 minutes before endoscopy improves visualization and reduces need for second-look endoscopy 2, 4
- Start high-dose PPI before endoscopy, but do not delay endoscopy for PPI administration 1, 4
Rebleeding Management
- First rebleeding: Repeat endoscopy with second attempt at hemostasis 1
- Second endoscopic failure: Consider transcatheter angiographic embolization or surgery 1, 2
- Routine second-look endoscopy is NOT recommended 1
H. pylori Management
- Test all patients for H. pylori in acute setting 1
- Initiate eradication therapy if positive
- Retest if initially negative (acute setting tests can be falsely negative)
- Confirm successful eradication 1
Antiplatelet Management
For patients on aspirin for secondary cardiovascular prophylaxis:
- Low-risk lesions (IIc, III): Resume aspirin immediately after index endoscopy 4
- High-risk lesions (Ia, Ib, IIa, IIb): Resume aspirin by day 3 after adequate hemostasis established 4
Critical pitfall: Do not use H2-receptor antagonists, somatostatin, or octreotide - these provide no benefit in acute ulcer bleeding 1.